EXERCISE OF WARRANTS OF SERIES TO2 (05 - 15 FEBRUARY 2026)
TO2 WARRANTS: Exercise period 05 – 15 February 2026
SUMMARY OF TERMS OF WARRANTS SERIES TO2
Market place: Nasdaq First North Growth Market
Subscription period for warrants of series TO2: 05 – 15 February 2026
Total outstanding warrants: 14 957 792
Each warrant entitle the holder to subscription of two (2) new shares resulting in a total possible new shares of 29 915 584 . If all warrants are exercised, the Company will receive approximately SEK 44.87 million before issuing costs.
Price for exercise of warrants of series TO2: SEK 1.50 per share.
TERMS: The exercise price for the warrants of series TO2 is to be determined to 70 per cent of the volume-weighted average price (VWAP) paid for the Company’s share on Nasdaq First North Growth Market during the measurement period, the ten (10) trading days preceding 05 February 2026, however, not less than SEK 1.50 and not more than SEK 3.00 per share.
For the warrants of series TO2 to not expire without value: it is required that the holder actively subscribes for new shares no later than on 15 February 2026.
Observe that certain banks/platforms might close the exercise option earlier than on 15 February 2026.
Possible Dilution: Upon full exercise of the warrants of series TO2, the number of shares will increase by 29 915 584 shares, from 42 084 415 to 71 999 999 and the share capital will increase by SEK 1,279,074.822922, from SEK 1,799,367.034382 to SEK 3,078,441.857304.
In the event that all warrants of series TO2 are exercised, the dilution amounts to approximately 41.55 per cent of the number of shares and votes in the Company.
Please note that warrants of series TO2 that are not exercised no later than on 15 February will expire without value. For warrants not to lose their value, the holder must actively subscribe for new shares.
Full terms:
For the full terms for the warrants of series TO2, please refer to FULL TO2 TERMS.
FOR ANY TECHNICAL QUESTIONS:
For holders of warrants of series TO2 with any technical questions, please contact the issuing agent Nordic Issuing on info@nordic-issuing.se
ISSUING INSTITUTION
Nordic Issuing
info@nordic-issuing.se
nordic-issuing.se
LEGAL COUNSEL
MAQS Advokatbyrå
INTERVIEW WITH DIREKT STUDIOS:
PILA PHARMA management team comments on TO2 warrants, preclinical study and the decision to proceed to the clinic.
Find the link to the video (In English) here
INTERVIEW WITH BIOSTOCK:
PILA PHARMA management team comments on TO2 warrants, preclinical study and the decision to proceed to the clinic.
Find the link to the interview (In English) here